Dermatoses of Childhood: 7 Photoclinic Cases

Slideshow

Can you diagnose these 7 cases of dermatoses? Scroll through our Photoclinic to find out. 

These seven Photoclinic cases offer a good look at and a brief overview of common dermatologic conditions of childhood. (This presentation updates the original, posted in 2016.)

Related Content
FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years / image credit DOCS Dermatology Rocco Serrao, MD

FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Grace Halsey
December 16th 2024
Article

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis / Image credit: ©Argus/AdobeStock

FDA Approves Nemolizumab for Treatment of Moderate-to-Severe Atopic Dermatitis

Sydney Jennings
December 16th 2024
Article

Nemolizumab is the first approved monoclonal antibody that targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives disease mechanism in atopic dermatitis.

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older / image credit ©Waldenmarus/stock.adobe.com

Tapinarof Cream, 1%, Gets FDA Green Light for Atopic Dermatitis in Individuals Aged 2 Years and Older

Grace Halsey
December 16th 2024
Article

Approval for the topical nonsteroidal therapy, based on data from the phase 3 ADORING clinical trial program, helps fill a gap in current offerings for atopic dermatitis.

Upadacitinib Effective for Atopic Dermatitis in Adolescents at 76 Weeks: RCT Analysis / image credit: Amy S Paller, MS, MD Courtesy of Northwestern Medicine

Upadacitinib Safe and Effective for Atopic Dermatitis in Adolescents at 76 Weeks: RCT Analysis

Joshua Fitch
December 11th 2024
Article

Upadacitinib (15 and 30 mg) was evaluated in adolescents with moderate to severe AD aged 12 to 17 years, with and without topical corticosteroids.

Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose / image credit: ©New Africa/AdobeStock

Dupilumab Effective for Severe Atopic Dermatitis at 5 Years: Daily Dose

Sydney Jennings
November 7th 2024
Article

Your daily dose of the clinical news you may have missed.

When is It Time to Refer: A Dermatologist Considers Atopic Dermatitis Treated in Primary Care / Image credit Central Connecticut Dermatology

When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care

Grace Halsey
November 7th 2024
Article

Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.

© 2024 MJH Life Sciences

All rights reserved.